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ABSTRACT
Motivation: Within any given tissue, gene expression levels can vary
extensively among individuals. Such heterogeneity can be caused by
genetic and epigenetic variability and may contribute to disease. The
abundance of experimental data now enables the identification of fea-
tures of gene expression profiles that are shared across tissues, and
those that are tissue-specific. While most current research is con-
cerned with characterising differential expression by comparing mean
expression profiles across tissues, it is also believed that a significant
difference in a gene expression’s variance across tissues may also be
associated with molecular mechanisms that are important for tissue
development and function.
Results: We propose a sparse multi-view matrix factorisation
(sMVMF) algorithm to jointly analyse gene expression measurements
in multiple tissues, where each tissue provides a different “view” of the
underlying organism. The proposed methodology can be interpreted
as an extension of principal component analysis in that it provides
the means to decompose the total sample variance in each tissue
into the sum of two components: one capturing the variance that
is shared across tissues, and one isolating the tissue-specific vari-
ances. sMVMF has been used to jointly model mRNA expression
profiles in three tissues obtained from a large and well-phenotyped
twins cohort, TwinsUK. Using sMVMF, we are able to prioritise genes
based on whether their variation patterns are specific to each tissue.
Furthermore, using DNA methylation profiles available, we provide
supporting evidence that adipose-specific gene expression patterns
may be driven by epigenetic effects.
Availability: Python code is available upon request.
Contact: giovanni.montana@kcl.ac.uk
1 INTRODUCTION
RNA abundance, as the results of active gene expression, affects
cell differentiation and tissue development (Coulon et al., 2013). As
such, it provides a snapshot of the undergoing biological process
within certain cells or a tissue. Except for house-keeping genes, the
expressions of a large number of genes vary from tissue to tissue,
and some may only be expressed in a particular tissue or a cer-
tain cell type (Xia et al., 2007). The regulation of tissue-specific
∗to whom correspondence should be addressed
expression is a complex process in which a gene’s enhancer plays
a key role regulating gene expressions via DNA methylation (Ong
and Corces, 2011). Genes displaying tissue-specific expressions are
widely associated with cell type diversity and tissue development
(Reik, 2007), and aberrant tissue-specific expressions have been
associated with diseases that originated in the underlying tissue
(van’t Veer et al., 2002; Lage et al., 2008). Distinguishing tissue-
specific expressions from expression patterns prevalent in all tissues
holds the promise to enhance fundamental understanding of the uni-
versality and specialization of molecular biological mechanisms,
and potentially suggest candidate genes that may regulate traits of
interest (Xia et al., 2007). As collecting genome-wide transcrip-
tomic profiles from many different tissues of a given individual is
becoming more affordable, large population-based studies are be-
ing carried out to compare gene expression patterns across human
tissues (Liu et al., 2008; Yang et al., 2011).
A common approach to detecting tissue-specific expressions con-
sists of comparing the mean expression levels of individual genes
across tissues. This can be accomplished using standard univariate
test statistics. For instance, Wu et al. (2014) used the two-sample
Z-test to compare non-coding RNA expressions in three embryonic
mouse tissues: they reported approximately 80% of validated in vivo
enhancers exhibited tissue-specific RNA expression that correlated
with tissue-specific enhancer activity. Yang et al. (2011) applied a
modified version of Tukey’s range test (Tukey, 1949), a test statistic
based on the standardised mean difference between two groups, to
compare expression levels of 127 human tissues, and results of this
study are publicly available in the VeryGene database. A related
database, TiGER (Liu et al., 2008), has also been created by com-
paring expression sequence tags (EST) in 30 human tissues using
a binomial test on EST counts. Both VeryGene and TiGER con-
tain up-to-date annotated lists of tissue-specific gene expressions,
which generated hypotheses for studies in the area of pathogenic
mechanism, diagnosis, and therapeutic research (Wu et al., 2009).
More recent studies have gone beyond the single-gene compari-
son and aimed at extracting multivariate patterns of differential gene
expression across tissues. Xiao et al. (2014) applied the higher-order
generalised singular value decomposition (HO-GSVD) method pro-
posed by Ponnapalli et al. (2011) and compared co-expression
networks from multiple tissues. This technique is able to highlight
c© Oxford University Press 2005. 1
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co-expression patterns that are equally significant in all tissues or
exclusively significant in a particular tissue. The rationale for a mul-
tivariate approach is that when a gene regulator is switched on, it
can raise the expression level of all its downstream genes in spe-
cific tissues. Hence a multi-gene analysis may be a more powerful
approach.
While most studies explore the differences in the mean of expres-
sion, the sample variance is another interesting feature to consider.
Traditionally, comparison of expression variances has been carried
out in case-control studies (Mar et al., 2011). Using an F-test,
significantly high or low gene expression variance has been ob-
served in many disease populations including lung adenocarcinoma
and colerectal cancer, whereas the difference in mean expression
levels was not found significant between cases and controls (Ho
et al., 2008). In a tissue-related study, Cheung et al. (2003) car-
ried out a genome-wide assessment of gene expressions in human
lymphoblastoid cells. Using an F-test, the authors showed that
high-variance genes were mostly associated with functions such
as cytoskeleton, protein modification and transport, whereas low-
variance genes were mostly associated with signal transduction and
cell death/proliferation.
In this work we introduce a novel multivariate methodology that
can detect patterns of differential variance across tissues. We regard
the gene expression profiles in each tissue as providing a differ-
ent “view” of the underlying organism and propose an approach
to carry out such a multi-view analysis. Our objective is to iden-
tify genes that jointly explain the same amount of sample variance
in all tissues – the ”shared” variance– and genes that explain sub-
stantially higher variances in each specific tissue separately – the
”tissue-specific” variances – while the shared variance has been ac-
counted for. During this process we impose a constraint that the
factors driving shared and tissue-specific variability must be uncor-
related so that the total sample variance can be decomposed into the
two corresponding components. The proposed methodology, called
sparse multi-view matrix factorisation (sMVMF), can be interpreted
as an extension of principal component analysis (PCA), which is
traditionally used to identify a handful of latent factors explaining a
large portion of sample variance separately in each tissue.
The rest of this paper is organised as follows. The sMVMF
methodology is presented in Section 2, where we also discuss con-
nections with a traditional PCA and derive the parameter estimation
algorithm. In Section 3 we demonstrate the main feature of the pro-
posed method on simulated data, and report on comparison with
alternative univariate and multivariate approaches. In Section 4 we
apply the sMVMF to compare mRNA expressions in three tissues
obtained from a large twin population, the TwinsUK cohort. We
conclude in Section 5 with a discussion.
2 METHODS
2.1 Sparse multi-view matrix factorisation
We assume to have collected p gene expression measurements for M dif-
ferent tissues. Ideally the data for all tissues should be derived from the
same underlying random sample (as in our application, Section 4) in or-
der to remove sources of biological variability that can potentially induce
differences in gene expression profiles across tissues. In practice, however,
cross-tissue experiments rarely collect samples from the same set of subjects
or may fail quality control. In our setting therefore we assume M differ-
ent random samples, each one contributing a different tissue dataset. The
mth dataset consists of nm subjects, and the expression profiles are ar-
ranged in an nm × p matrix. All matrices are collected in X = {X(1),
X(2), ..., X(M)}, where the superscripts refer to tissue indices. For each
X(m), we subtract the column mean from each column such that each diag-
onal entry of the scaled gram matrix, 1
nm
(X(m))TX(m), is proportional
to the sample variance of the corresponding variable, and the trace is the
total sample variance. We aim to identify genes that jointly explain a large
amount of sample expression variances in all tissues and genes that explain
substantially higher variances in a specific tissue. Our strategy involves ap-
proximating each 1√
nm
X(m) by the sum of a shared variance component
and a tissue-specific component:
1√
nm
X(m) ≈ S(m)︸ ︷︷ ︸
shared variance component
+ T (m)︸ ︷︷ ︸
tissue-specific variance component
(1)
for m = 1, 2, ...,M , where 1/
√
nm is a scaling factor such that the trace
of the gram matrix of the left-hand-side equals the sample variance. These
components are defined so as to yield the following properties:
(a) The rank of S(m) and T (m) are both much smaller than min(n, p) so
that the two components provide insights into the intrinsic structure of
the data while discarding redundant information.
(b) The variation patterns captured by shared component are uncorrelated
to the variation patterns captured by tissue-specific component. As a
consequence of this, the total variance explained by S(m) and T (m)
altogether equals the sum of the variance explained by each individual
component.
(c) The shared component explains the same amount of variance of each
gene expression in all tissues. As such, the difference in expres-
sion variance between tissues is exclusively captured in tissue-specific
variance component.
We start by proposing a factorisation of both S(m) and T (m) which,
by imposing certain constraints, will satisfy the above properties. Suppose
rank(S(m)) = d and rank(T (m)) = r, where d, r << min(n, p) follow-
ing property (a). For a given r, T (m) can be expressed as the product of an
n × r full rank matrix W (m) and the transpose of a p × r full rank matrix
V (m), that is:
T (m) = W (m)(V (m))T =
r∑
j=1
W
(m)
j (V
(m)
j )
T =
r∑
j=1
T
(m)
[j]
(2)
where the superscript T denotes matrix transpose, and the subscript j
denotes the jth column of the corresponding matrix. Each T (m)
[j]
:=
W
(m)
j (V
(m)
j )
T has the same dimension as T (m) and is composed of a
tissue-specific latent factor (LF). A LF is an unobservable variable assumed
to control the patterns of observed variables and hence may provide insights
into the intrinsic mechanism that drives the difference of expression vari-
ability between tissues. The matrix factorisation in (2) is not unique, since
for any r × r non-singular square matrix R, T (m) = W (m)(V (m))T =
(W (m)R)(R−1(V (m))T ) = W˜ (m)(V˜ (m))T . We introduce an orthog-
onal constraint (W (m))TW (m) = Ir so that the matrix factorisation is
unique subject to an isometric transformation. Similarly, we can factorise
the shared component as:
S(m) = U(m)(V ∗)T =
d∑
k=1
U
(m)
k (V
∗
k )
T =
d∑
k=1
S
(m)
[k]
(3)
where U(m) is orthogonal and V ∗ is tissue-independent which we shall
explain. EachS(m)
[k]
has the same dimension asS(m) and is composed of one
shared variability LF. The resulting multi-view matrix factorisation (MVMF)
then is:
1√
nm
X(m) ≈ U(m)(V ∗)T +W (m)(V (m))T (4)
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The matrix factorisations (2) and (3) are intimately related to the singu-
lar value decomposition (SVD) of S(m) and T (m). Specifically, U(m) and
W (m) are analogous to the matrix of left singular vectors and also the prin-
cipal components (PCs) in a standard PCA. They represent gene expression
patterns in a low-dimensional space where each dimension is derived from
the original gene expression measurements such that the maximal amount
of variance is explained. We shall refer the columns of U(m) and W (m) as
the principal projections (PPJ). (V ∗)T and (V (m))T are analogous to the
product of the diagonal matrix of eigenvalues and the matrix of right sin-
gular vectors. Since the singular values determine the amount of variance
explained and the right singular vectors correspond to the loadings in the
PCA which quantifies the importance of the genes to the expression variance
explained, using the same matrix V ∗ for all tissues in the shared component
results in the same amount of shared variability explained for each gene ex-
pression probe, such that property (c) is satisfied. We shall refer to matrices
V ∗ and V (m) as transformation matrices.
A sufficient condition to satisfy property (b) is:
(U(m))TW (m) = 0d×r (5)
This constraint, in addition to the orthogonality of U(m) and W (m), results
in the (d+r) PPJs represented by [U(m),W (m)] being pairwise orthogonal,
which is analogous to the standard PCA where the PCs are orthogonal. Intu-
itively, this means for each tissue the LFs driving shared and tissue-specific
variability are uncorrelated. The amount of variance explained in tissue m,
σˆsm, can be computed as (subject to a constant factor):
σˆsm = Tr{(S(m))TS(m) + (T (m))TT (m) + 2(S(m))TT (m)} (6)
where Tr denotes the matrix trace. Recalling that S(m) = U(m)V ∗ and
(U(m))TU(m) = Id, the amount of shared variance explained is:
σ∗ = Tr{(S(m))TS(m)} = Tr{V ∗(V ∗)T } (7)
Likewise, recalling that T (m) = W (m)(V (m))T and (W (m))TW (m) =
Ir , the amount of tissue-specific variance explained is:
σm = Tr{(T (m))TT (m)} = Tr{V (m)(V (m))T } (8)
Making the same substitutions into (6), we obtain:
σˆsm = Tr{V ∗(V ∗)T + V (m)(V (m))T + 2V ∗(U(m))TW (m)(V (m))T }
Substituting (5) into the above equation, we reach:
σˆsm = Tr{V ∗(V ∗)T + V (m)(V (m))T } = σ∗ + σm (9)
which satisfies (b).
2.2 Sparsity constraints and estimation
The factorisation (4) is obtained by minimising the squared error. This
amounts to minimising the loss function:
` =
M∑
m=1
‖ 1√
nm
X(m) − U(m)(V ∗)T −W (m)(V (m))T ‖2F (10)
where ‖.‖F refers to the Frobenius norm, subject to the following orthogo-
nality constraints:
(U(m))TU(m) = I, (W (m))TW (m) = I, (U(m))TW (m) = 0. (11)
For fixed U(m)(V ∗)T , the optimal T (m) = W (m)(V (m))T is a
low-rank approximation of ‖ 1√
nm
X(m) − S(m)‖2F , where each rank se-
quentially captures the maximal variance remained in each data matrix after
removing the shared variability. Likewise, for fixed W (m)(V (m))T , each
rank of the optimal S(m) = U(m)(V ∗)T sequentially captures the max-
imal variance remained across all tissues after removing the tissue-specific
variance.
In transcriptomics studies, it is widely believed that the differences in
gene expressions between cell and tissue types are largely determined by
transcripts derived from a small number of tissue-specific genes (Jonge-
neel et al., 2005). Therefore it seems reasonable that in our application of
multi-tissue comparison of gene expressions, for each PPJ, the correspond-
ing column in the transformation matrix should feature a limited number of
non-zero entries. In such a scenario, a sparse representation will not only
generate more reliable statistical models by excluding noise features, but
also offer more biological insight into the underlying cellular mechanism
(Ma and Huang, 2008).
In the context of MVMF, we induce sparse estimates of V ∗ and V (m)
by adding penalty terms to the loss function ` (U,W, V ∗, V ) as in (10).
Specifically, we minimise:
` (U,W, V ∗, V ) + 2 ·M · ‖V ∗Λ∗‖1 + 2
M∑
m=1
‖V (m)Λ(m)‖1 (12)
where ‖ ‖1 denotes the `1 norm. Λ∗ and Λ(m) are d×d and r× r diagonal
matrices, respectively. In both matrices, the kth diagonal entry is a non-
negative regularisation parameter for the kth column of the corresponding
transformation matrix, and the kth column tends to have more zero entries as
the kth diagonal entry increases. In practice, a parsimonious parametrisation
may be employed where Λ∗ = λ1Id and Λ(m) = λ2Ir for m = 1, ...,M
so that the number of parameters to be specified is greatly reduced. Alterna-
tively, Λ∗ and Λ(m) may be set such that a specified number of variables are
selected in each column of Vˆ ∗ and Vˆ (m).
The optimisation problem (12) with constraints (11) is not jointly con-
vex in U(m),W (m), V (m), and V ∗ for m = 1, 2, ...,M (for instance the
orthogonality constraints are non-convex in nature), hence gradient descent
algorithms will suffer from multiple local minima (Gorski et al., 2007). We
propose to solve the optimisation problem by alternately minimising with
respect to one parameter inU(m),W (m),V ∗, V (m) while fixing all remain-
ing parameters, and repeating this procedure until the algorithm converges
numerically. The minimisation problem with respect to V ∗ or V (m) alone is
strictly convex, hence in these steps a coordinate descent algorithm (CDA) is
guaranteed to converge to the global minimum (Friedman et al., 2007). CDA
iteratively update the parameter vector by cyclically updating one component
of the vector at a time, until convergence. On the other hand, the minimisa-
tion problem with respect to W (m) or U(m) is not convex. For fixed V ∗
and V (m), the estimates of W (m) and U(m) that minimise (12) can be
jointly computed via a closed form solution. Assuming we have obtained
initial estimates of V ∗ and V (m), we cyclically update the parameters in
the following order:
(U(m),W (m))→ V (m) → V ∗
HereU(m) andW (m) are jointly estimated in the first step, and in the subse-
quent steps V (m) and V ∗ are updated separately, while keeping the previous
estimates fixed. A detailed explanation of how each update is performed is
in order.
First we reformulate the estimation problem as follows: we bind the
columns of U(m) andW (m) and define the n× (d+ r) augmented matrix:
U˜(m) = [U(m) , W (m)]; we then bind the columns of V ∗ and V (m) and
define the p× (d+ r) matrix: V˜ (m) = [V ∗ , V (m)]. As such:
` (U,W, V ∗, V (m)) =
M∑
m=1
‖ 1√
nm
X(m) − U˜(m)(V˜ (m))T ‖2F
and the constraints in (11) can be combined into:
(U˜(m))T U˜(m) = Id+r
Fixing V˜ (m), the estimate of U˜(m) can be obtained by the reduced-rank
Procrustes rotation procedure which seeks the optimum rotation of X(m)
such that the error ‖ 1√
nm
X(m) − U˜(m)(V˜ (m))T ‖2F is minimal. For a
proof of this, see (Zou et al., 2006). We obtain the SVD of 1√
nm
X(m)V˜ (m)
as PQRT , and compute the estimate of U˜(m) by: ˆ˜U(m) = PRT .
Next, we fixU(m),W (m), and V ∗ while minimising (12) with respect to
V (m). For each fixed m, varying V (m) only changes the objective function
3
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via the summand indexed (m). Hence it is sufficient to minimise:
‖ 1√
nm
X(m) − U(m)(V ∗)T −W (m)(V (m))T ‖2F + 2‖V (m)Λ(m)‖1.
(13)
This function is strictly convex in V (m) and the CDA is guaranteed to con-
verge to the global minimum. We drop the superscript (m) in the following
derivation for convenience and denote the jth column of the matrix V by Vj .
In each iteration, the estimate of Vj is found by equating the first derivative
of (13) with respect to Vj to zero. Hence:
−2( 1√
nm
X − UV ∗ −WV T )TWj + 2Λj · ∇(|Vj |) = 0,
where∇ is the gradient operator. Substitute (11) and rearrange to give:
Vj =
1√
nm
XTWj − Λj · ∇(|Vj |)
We define the sign function σ(y) which equals 1 if y > 0, −1 if y < 0,
and 0 if y = 0. First note the derivative of the function |y| is σ(y) if y 6= 0
and a real number in the interval (−1, 1) otherwise. Rearrange the previous
equation to obtain the updated estimate in each iteration:
Vˆ
(m)
j = SΛ(m)j
(
(
1√
nm
X(m))TW
(m)
j
)
(14)
where Sλ(y) is a soft-thresholding function on vector y with non-negative
parameter λ such that Sλ(y) = σ(y) · max{|y| − λ, 0}, and Λ(m)j is the
jth diagonal entry of Λ(m).
In the third step, we fix the estimates of U(m), W (m), and V (m) and
minimise (12) with respect to V ∗. The objective function becomes:
`+ 2 ·M · ‖V ∗Λ∗‖1 (15)
where ` is defined in (10). As in the second step, we use a CDA in each iter-
ation and the updated estimate of V ∗i is found by equating the first derivative
of (15) to zero. Specifically:
−2∑Mm=1 {[ 1√nmX(m) − U(m)V ∗ −W (m)(V (m))T ]TUi
}
+ 2 ·M · Λ∗i · ∇(|V ∗i |) = 0,
where Λ∗i is the i
th diagonal entry of Λ∗. Applying (11), this can be re-
arranged into:
M · V ∗i =
M∑
m=1
(
1√
nm
X(m))TU
(m)
i −M · Λ∗i · ∇(|V ∗i |),
Using the soft-thresholding and the sign functions, the updated estimate in
each iteration can be re-written as:
Vˆ ∗i = SΛ∗i
(
1
M
M∑
m=1
(
1√
nm
X(m))TU
(m)
i
)
(16)
The cyclic CDA requires initial estimates of V ∗ and V (m), which are ob-
tained as follows. First we set an initial value to V ∗, which explains as much
variance in all datasets in X as possible. This amounts to a PCA on the
(
∑M
m=1 nm)× p matrix Xˇ obtained by binding the rows of all data matri-
ces 1√
nm
X(m), m = 1, ...,M . We compute the truncated SVD of Xˇ and
obtain Xˇ = UˇDBT where D contains the d largest eigenvalues of XˇT Xˇ .
The initial estimate of V ∗ is then defined as:
(Vˆ ∗)T =
1
M
DBT , (17)
and Uˆ(m) is defined by the corresponding rows of Uˇ in the SVD. For the
tissue-specific transformation matrices V (m), we compute the SVD of the
residuals after removing the shared variance component from 1√
nm
X(m),
which gives: 1√
nm
X(m)− Uˆ(m)Vˆ ∗ = W (m)R(m)(Q(m))T . The initial
estimate of V (m) is defined as:
(Vˆ (m))T = R(m)(Q(m))T . (18)
A summary of the estimation procedure is given in Algorithm 1.
Algorithm 1 sMVMF estimation algorithm
Input: data X ; parameters d, r, Λ(m), Λ∗ for m = 1, 2, ...,M .
Output: U (m), W (m), V (m), for m = 1, 2, ...,M , and V ∗.
1: Get initial estimates of V (m) for m = 1, 2, ...,M , and V ∗ as in
(18) and (17).
2: while not convergent do:
3: Apply SVD: 1√
nm
X(m)V˜ (m) = PQRT , and set ˆ˜U (m) =
PRT .
4: Use CDA to estimate V (m) according to (14).
5: Use CDA to estimate V ∗ according to corollary (16).
The sMVMF contains two sets of parameters: the tissue-specific spar-
sity parameters Λ(m), Λ∗, and the (d, r) pair. Both d and r balance model
complexity and the amount of variance explained. We select the smallest
possible values of d and r such that a prescribed proportion of variance is
explained. For a fixed (d, r) pair, we propose to optimise the model with
respect to the choice of sparsity parameters using a variable selection proce-
dure called “stability selection”, which is particularly effective in improving
variable selection accuracy and reducing the number of false positives in
high-dimensional settings (Meinshausen and Bu¨hlmann, 2010). Stability se-
lection consists of fitting the sparse model to a large number of randomly
generated subsamples, each of which typically contains half of the subjects.
Variable selection results across all subsamples are collected to compute em-
pirical selection probabilities. A cutoff probability value is then chosen and
the variables whose selection probability is larger than this threshold are se-
lected by this procedure. One of the appealing features of this approach is
that the ranking of variables, especially the high-ranking variables, is gen-
erally insensitive to the choice of regularisation parameters. An overview of
the stability selection procedure is given in Supplementary Material, Section
A.
3 ILLUSTRATION WITH SIMULATED DATA
In this section we present simulation studies to characterise how the sMVMF
method is able to distinguish between shared and tissue-specific variance.
We simulate shared and tissue-specific variance patterns as illustrated by the
middle and right panels in Figure 1. We then test whether sMVMF correctly
decomposes the total sample variance (left panel) whilst detecting variables
contributing to the non-random variability within each variance component.
We also compare sMVMF with two alternative methods: standard PCA and
Levene’s test (Gastwirth et al., 2009) of the equality of variance between
population groups.
3.1 Simulation setting
Our simulation study consists of 1000 independent experiments. In each
experiment we simulate 3 data matrices or datasets (tissues) of dimension
n = 100 (samples) and p = 500 (genes). Each simulated data matrixX(m)
is obtained via:
X(m) = Y (m) + Z(m) + E(m),
where Y (m) is a component designed to control the shared variance, Z(m)
is introduced to control the tissue-specific variance, and E(m) is a random
error. They are all n × p random matrices. Since we ultimately wish to test
whether our method is able to distinguish between signal and noise vari-
ables, we assume that only the first 30 variables carry the signal, whereas
the remaining 470 only introduce noise.
We suppose that the shared variability is controlled by the activation of 3
latent factors, each regulating the variance of a different block of variables.
To this end, we further group the 30 signal variables into three blocks of 10
normally distributed random variables each (numbered 1− 10,11− 20, and
21 − 30), as illustrated in Figure 2 (A). We design the simulations so that
4
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each of the first 30 variables in Y has the same variance in different datasets;
moreover, the variance decreases while moving from the first to the third
block. Further details and simulation parameters are available in the Sup-
plementary Material, Section B. This procedure generates shared variance
patterns that look like those reported in the middle panel of Figure 1.
The variables in Z are also assumed to be normally distributed. They
are generated such that exactly 10 of them have the largest variance across
datasets. The resulting ”mosaic” structure of the simulated variance patterns
is illustrated in right panel of Figure 1. The data matrices Y (m) and Z(m)
are generated such that the total non-random sample variance of each vari-
able in a tissue equals the sum of its shared and tissue-specific variances,
which is also illustrated in Figure 1. The random error term E(m) is gen-
erated from independent and identical standard normal distributions for all
variables in all datasets. As a result of this simulation design, we are able
to characterise the true underlying architecture that explains the total sample
variance.
3.2 Simulation results
The data generated in each experiment was analysed by fitting the sMVMF
algorithm. In order to focus on the ability of the model to disentangle the
true sources of variability, we take d = 3 and r = 1, which equal the
true number of shared and tissue-specific LFs used to generate the data. The
regularisation parameters Λ∗ and Λ(m) are tuned such that each PPJ consists
of 10 variables, the true number of signal variables.
For comparison, we propose two additional approaches that are able to
identify variables featuring dataset-specific sample variances, although they
do not attempt to model the shared variance. The first method consists of
carrying out a separate PCA on each dataset; for each PCA/dataset, we then
select the 10 variables having the largest loadings in the first principal com-
ponent. The second method consists of applying a standard Levene’s test
of equality of population variances independently for each variable, which
is then followed by a Bonferroni adjustment to control the family-wise error
rate; if a test rejects the null hypothesis at the 5% significance level, we select
the variable having the largest sample variance amongst the three datasets.
By averaging across 1000 experiments, we are able to estimate the prob-
ability that each one of the 30 signal variables is selected by each one of
the three competing methods. The heatmaps (A)-(C) in Figure 3 visually
represent these selection probabilities. Here sMVMF perfectly identifies the
variables that introduce dataset-specific variability. The results obtained us-
ing Levene’s tests are somewhat similar, except for some variables in the
first block (indexed 3 − 8) and second block (indexed 14 − 17). By ref-
erence to the middle panel of Figure 1, it can be noted that these variables
are precisely those featuring large shared variability by construction. On the
other hand, the PCA-based approach performs poorly because it can only
select variables that contribute to explaining the total sample variance, but
is unable to capture dataset-specific patterns. This example is meant to illus-
trate the limitations of both univariate and multivariate approaches that do
not explicitly account for factors driving shared and dataset-specific effects.
sMVMF has been designed to address exactly these limitations.
Both Levene’s test and the individual-PCA approach are not designed
to capture shared variance patterns. As a way of direct comparison with
sMVMF we therefore propose an alternative PCA-based approach that has
the potential to identify variables associated to the direction of largest vari-
ance across all three datasets. This method consists of performing a single
PCA on a “stacked” matrix of dimension (Mn) × p containing measure-
ments collected from all three datasets, and obtained by coalescing the rows
of the three individual data matrices. By varying the cutoff value for thresh-
olding the loadings of the first PC, we are able to select the top 10, 20, and
30 variables. We shall refer to this approach as stacked-PCA.
Results produced by sMVMF and stacked-PCA are summarised by the
heatmaps (B) and (C) in Figure 2, and can be directly compared to the true
simulated patterns in (A). As expected, stacked-PCA tends to select variables
having large total sample variances, whereas sMVMF can identify variables
affected by each shared LF which jointly explain a large amount of variance.
Figure 1: Simulated patterns of sample variance: the total, non-
random, sample variance of 30 signal-carrying random variables is
generated so that it can be decomposed into the sum of shared and
tissue-specific components. Rows correspond to tissues (datasets)
and columns correspond to 30 variables. Brighter colours represent
large variance and darker colours represent low variance. Although
by construction the underlying shared and tissue-specific vari-
ances have very different patterns, sMVMF is able to discriminate
between them.
Figure 2: Each latent factor (LF) is only active in a block of 10
signal- carrying variables, and controls the amount of variance of
those variables that is shared amongst datasets. The (A) panel shows
the true latent structure used to generate the data. Panels (B) and (C)
show the estimated probabilities that each variable has been selected
as signal-carrier using sMVMF and a stacked-PCA approach, re-
spectively. sMVMF accurately captures the true shared LF structure
whereas stacked-PCA tends to identify variables with large variance
but fails to identify the LF structure.
Figure 3: Three different methods – sMVMF, Levene’s test and
PCA – are used to detect random variables whose variance pattern
is dataset-specific. Each heatmap represents the selection probabili-
ties estimated by each method: (A) sMVMF produces patterns that
closely match the true tissue-specific variances shown in the right
panel of Figure 1; (B) Levene’s test performs well for variables
those variance is mostly driven by tissue-specific factors, but fails to
detect those variables having a strong shared-variance component;
(C) The PCA-based method cannot distinguish between shared and
tissue-specific variability, and fails to recover the true pattern.
This example shows that sMVMF is able to identify the variables associated
to the latent factors controlling the shared variance.
We also carried out a simulation, based upon the same setting, with
smaller signal-to-noise ratio, i.e. by sampling the random error terms in
E(m) from independent normal distributions having larger variance. The re-
sults were very similar to the previous setting, except that Levene’s test was
hardly able to identify any tissue-specific genes. The heatmaps summarising
model performances are given in Supplementary Material, Section C.
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4 APPLICATION TO THE TWINSUK COHORT
4.1 Data preparation
TwinsUK is one of the most deeply phenotyped and well-
characterised adult twin cohort in the world (Moayyeri et al., 2013).
It has been widely used in studying the genetic basis of aging pro-
cession as well as complex diseases (Codd et al., 2013). More
importantly, it contains a broad range of ‘omics’ data including ge-
nomic, epigenomic and transcriptomic profiles amongst others (Bell
et al., 2012). In this study, we focus on comparing the variance
of mRNA expressions in adipose (subcutaneous fat), lymphoblas-
toid cell lines (LCL), and skin tissues. The microarray data used in
this study were obtained from the Multiple Tissue Human Expres-
sion Resource (Nica et al., 2011), with participants being recruited
from the TwinsUK registry. Peripheral blood samples were artifi-
cially transformed from mature blood cells by infecting them with
the Epstein-Barr virus (Glass et al., 2013). All tissue samples were
collected from 856 female Caucasian twins (154 monozygotic twin
pairs, 232 dizygotic twin pairs and 84 singletons) aged between 39
and 85 years old (mean 62 years). Genome-wide expression pro-
filing was performed using Illumina Human HT-12 V3 BeadChips,
which included 48,804 probes. Log2-transformed expression sig-
nals were normalized per tissue using quantile normalization of
the replicates of each individual followed by quantile normaliza-
tion across all individuals, as described in Nica et al. (2011). In
addition, we also had access to 450K methylation data of the same
adipose biopsies profiled using Infinium HumanMethylation 450K
BeadChip Kit (Wolber et al., 2014). We only retained probes whose
expression levels were measured in all three tissues, and removed
subjects comprising unmeasured expressions in any tissue. Using
the same notation introduced before, this resulted in three data ma-
trices each of dimension n = 618 and p = 26017. For each probe
in each tissue, a linear regression model was fitted to regress out the
effects of age and experimental batch, following the same procedure
as in Grundberg et al. (2012). Residuals in adipose, LCL, and skin
tissues were arranged in n × p matrices X(1), X(2), X(3), respec-
tively, for further analysis using the proposed multiple-view matrix
factorisation method.
4.2 Experimental results
Non-sparse MVMF was initially fitted for all combination of pa-
rameter pairs (d, r) in a grid. For each model fit, we computed the
percentage of variance explained in each tissue. These are shown in
the 3D bar charts presented in the Supplementary Material, Figure
S5. The percentages of variance explained varied between 25.2%
(d = r = 1, LCL) and 87.3% (d = r = 160, skin). The follow-
ing analyses are based on the d = r = 3 setting, which explains
at least 40% of expression variance across tissues. Given that there
are more than 26000 probes, and this is much larger than the sample
size, this choice of parameters offers a good balance between dimen-
sionality reduction and retaining a large portion of total variance.
Although two other combinations of (d, r), i.e. (2, 4) and (4, 2),
also explain a similar amount of total variance, we have found that
the gene ranking results are not extremely sensitive to these val-
ues. For more details on this sensitivity analysis, see Supplementary
Material, Section D.
The sparse version of our model, sMVMF, was then fitted to each
subsample in stability selection procedure to rank gene expressions
explaining a large amount of shared and tissue-specific variances
Figure 4: TwinsUK study: resulting SPOW plot. The wheel com-
prises four rings, which correspond to shared, adipose-, LCL-, and
skin-specific variability from the inner ring. It is also evenly di-
vided into 3274 fan slices, corresponding to 3274 mRNA expression
probes that are selected at least once in all subsamples. Probes
are re-ordered by their selection probabilities in the transformation
matrix in the shared component. Brighter colour denotes higher
probability, whereas darker colour denotes lower probability. We
are particularly interested in probes with high selection probability
exclusively in one ring.
respectively. A detailed description of the procedure is presented in
Supplementary Material, Section A. In summary, 1000 random sub-
samples were generated each consisting of 309 subjects randomly
and independently sampled without replacement from a total of 618.
No twin pair was included in any subsample in order to remove
possible correlations due to zygosity. sMVMF was fitted to each
subsample, where the sparsity parameters were fixed such that each
column of the transformation matrices comprised exactly 100 non-
zero entries. There were 3274 mRNA expression probes that were
selected at least once from any of the transformation matrices.
Probes that explain a large amount of expression variance exclu-
sively in one tissue are of particular interest. To make such probes
visually discernible we propose a new visualisation tool, the SPOW
(Selection PrObability Wheel) plot. The plot in figure 4 consists of
3274 fan slices corresponding to probes that are selected at least
once in all subsamples, re-ordered by their selection probabilities
in Vˆ ∗. The wheel is further divided into four rings, representing
shared, adipose-, LCL-, and skin tissue, respectively. Each ring
is assigned a unique colour spectrum to illustrate selection proba-
bilities of the probes: brighter colours denote a higher probability
and darker colours denote a lower probability. Probes featuring ex-
clusively shared or tissue-specific variability can be found along
the radii where only one part is painted in a bright colour and the
other three parts are colored in black. The SPOW plots for the
top 200 probes that explain shared and tissue-specific variability re-
spectively are presented in Supplementary Material Figures S6-S9,
where such probes can be more easily captured.
Four groups of mRNA expressions were selected for further in-
vestigation, corresponding to shared-exclusive, adipose-, LCL-, and
skin-exclusive expressions. Each group consisted of probes whose
selection probabilities were larger than 0.5 in the corresponding
transformation matrix and less than 0.005 in the other transfor-
mation matrices. These thresholds were set to give a manageable
number of featured gene probes while tolerating occasional selec-
tion in the other groups. This procedure selected 294 genes for
further study, including 114 adipose-exclusive, 83 LCL-exclusive,
64 skin-exclusive, and 33 shared-exclusive genes. We summarise
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the results in Table 1. A Venn-diagram representation of the results
is given in Supplementary Material, Section E.
Table 1. TwinsUK study: summary of results. There are additionally 33
shared-exclusive genes.
% of variance % of variance Number Number
explained by explained by of tissue- of tissue-
tissue-specific shared exclusive exclusive
component component probes genes
Adipose 27.0 14.7 132 114
LCL 30.8 12.1 91 83
Skin 32.6 11.5 74 64
For each tissue, we performed an enrichment test by overlapping
genes in our list with genes contained in the TiGER and Very-
Gene databases to examine the extent of agreement. In addition,
a Gene Ontology (GO) biological process pathway enrichment test
(Ashburner et al., 2000) and a Cytoscape pathway (CP) analysis
(Saito et al., 2012) were carried out to reveal the function of the
pathways which the 261 tissue-exclusive genes belonged to, and
FDR-corrected p-values were reported (See Supplementary Mate-
rial, Table T1 and T2 for full results). Below we present test results
for each group of genes separately for each tissue. We also report
the selection probability (SP) for some selected probes.
Skin-exclusive genes. 15 of the 64 genes from our skin-exclusive
list are contained in the combined TiGER/VeryGene list, giving rise
to significant enrichment of our list with Fisher exact test p-value
p < 10−16. The overlapping genes include serine protease fam-
ily genes KLK5 (SP: 1.000) and KLK7 (SP: 1.000), which are
highly expressed in the epidermis and related to various skin condi-
tions, such as cell shedding (desquamation) (Brattsand and Egelrud,
1999). Another member ALOX12B (SP: 1.000) controls produc-
ing 12R-LOX, which adds an oxygen molecule to a fatty acid to
produce the 12R-hydroperoxyeicosatetraenoic acid that has major
function in the skin cell proliferation and differentiation (de Juanes
et al., 2009). The skin-exclusive genes have also been found sig-
nificantly enriched in two biological processes, namely epidermis
development and cell-cell adhesion (p < 0.001 and p = 0.03,
respectively).
LCL-exclusive genes. LCLs are not natural human cells: they are
laboratory induced immortal cells that have abnormal telomerase
activity and tumorigenic property (Sie et al., 2009). Since neither
TiGER nor VeryGene assessed transcriptomic profile in LCL cells,
we obtained LCLs data from Li et al. (2010), in which the authors
compared LCLs expression profile in four human populations and
reported 282 LCL specific expression genes. 9 of those genes are
contained in our LCL-exclusive gene list, giving a Fisher exact test
p < 10−16. These include CDK5R1 (SP: 0.961) and HEY1 (SP:
1.000), which are key genes in the transformation of B lymphocytes
to LCLs (Zhao et al., 2006). Pathway analysis of the LCL-exclusive
genes reveals several aging and cell-death related pathways such as
regulation of telomerase (CP enrichment test, p = 0.014), small cell
lung cancer (CP enrichment test, p = 0.019), and cell cycle check-
points (CP enrichment test, p = 0.021). These results show that
our tissue-exclusive genes represent tissue unique molecular func-
tions and biological pathways, which may be used to validate known
pathways or discover new biological mechanisms.
Adipose-exclusive genes. ApoB (SP: 1.000) is the only member
in our adipose-exclusive list which is also contained in the list of
known adipose-specific expression genes (Fisher exact test, p =
0.05). ApoB is one of the primary apolipoproteins that transport
cholesterol to peripheral tissues (Knott et al., 1986) and it has been
widely linked to fat formation (Riches et al., 1999). In adipose,
the selected genes are found significantly enriched in triglyceride
catabolic process pathway (p = 0.022), which is in line with
the fact that adipose tissue is the major storage site for fat in
the form of triglycerides. Pathway analysis reveals that genes in
the adipose-exclusive list are significantly enriched in triglyceride
catabolic process pathway (p = 0.022), which agrees with the fact
that adipose tissue is the major storage site for fat in the form of
triglycerides. In addition, these genes are enriched in inflamma-
tion pathways, such as lymphocyte chemotaxis (p = 0.016) and
neutrophil chemotaxis (p = 0.027). This coincides with previous
findings of the complex and strong link between metabolism and
immune system in adipose tissue (Tilg and Moschen, 2006).
For this tissue we were also able to further investigate the causes
for the observed adipose-exclusive gene expression variability. One
possible explanation could be that environmental factors influenced
an individual’s epigenetic status, which subsequently regulated gene
expression (Razin and Cedar, 1991). As a mediator of gene regula-
tory mechanisms, DNA methylation is crucial to genomic functions
such as transcription, chromosomal stability, imprinting, and X-
chromosome inactivation (Lokk et al., 2014), which consequently
influence an individual’s tissue development (Ziller et al., 2013). It
thus seemed reasonable to hypothesise that the expression of tissue-
exclusive genes could be modified by their methylation status in the
same tissue.
We sought to identify genes featuring a statistically significant
linear relationship between the gene’s methylation profile and its
expression value from the same tissue. In adipose biopsies, where
both transcriptome and methylation data is available, we found that
68.4% (78 out of 114 genes) of the genes had expression levels
significantly associated with their methylation status using a linear
fit (Bonferroni correction, p < 0.05) (See Supplementary Mate-
rial, Table T3, for full lists). We then wanted to assess whether
a similar number of linear associations could be found by chance
only by randomly selecting any genes, not only those that feature
adipose-exclusive variability, and testing for association between
gene expression and methylation levels. This was done by ran-
domly extracting the same, fixed number (132) of expression probes
and corresponding methylation levels from adipose tissue, and fit-
ting a linear model as before. By repeating this experiment 1000
times, we obtained the empirical distribution reported in Figure
S10, Supplementary Material. This distribution suggested that all
the proportions were below 0.2, compared to our observed propor-
tion of 0.684, which provided overwhelming evidence that DNA
methylation was an important factor affecting the expression of the
tissue-exclusive genes. It was notable that the adipose-exclusive
variability of ApoB was regulated by methylation at 50bp upstream
of the Transcriptional Starting Site (linear fit, p = 2.1 × 10−5),
which agreed with the findings that the promoter of ApoB has tissue-
specific and species-specific methylation property (Apostel et al.,
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2002). Apart from ApoB, we also found that methylation in Syk
was associated with Syk expression level, which was potentially
involved in B cell development and cell apoptosis (Ma et al., 2010).
5 CONCLUSION
The proposed sMVMF method facilitates the comparison of gene
expression variances across multiple tissues. The primary chal-
lenge of this task arises from the interference between substantial
co-variability of gene expressions across all tissues and substan-
tial variability of gene expressions featured only in specific tissues.
Characterising tissue-specific variability can shed light on the bi-
ological processes involved with tissue differentiation. Analysing
shared variability can potentially reveal genes that are involved in
complex or basic biological processes, and may as well enhance the
estimation of tissue-specific variability.
sMVMF has been used here to compare gene expression vari-
ances in three human tissues from the TwinsUK cohort. 261 genes
having substantial expression variability exclusively featured in
one tissue have been identified. Enrichment tests showed signifi-
cant overlaps between our lists of tissue-exclusive genes and those
reported in the TiGER and VeryGene databases, which were es-
tablished by comparing mean expression levels. This confirms the
link between tissue-specific expression variance and the biological
functions associated with particular tissues. In future work, it would
be interesting to explore the functions of the tissue-exclusive genes
from our list that have not been reported in existing databases. We
further showed adipose-exclusive expression variability was driven
by an epigenetic effect. Using these results as a guiding principle,
we expect our methods and results could improve efficiencies in
mapping functional genes by reducing the multiple testing and en-
hancing the knowledge of gene function in tissue development and
disease phenotypes. Future works would consist of investigating the
outcome of tissue-exclusive expression variability, for which we can
perform association studies between expressions of tissue-exclusive
genes and disease phenotypes related to adipose and skin tissues.
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